Sanofi-Synthelabo Recherche Selects Tripos for Drug Discovery Partnership
Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry and informatics products and services, today announced that it has entered a strategic partnership with Sanofi-Synthelabo Recherche, an affiliate of Sanofi-Aventis (NYSE:SNY).
Sanofi-Synthelabo Recherche has identified a number of proprietary chemistry motifs that exhibit therapeutic potential in a wide range of target areas. Tripos will employ its knowledge-driven chemistry approach to design and synthesize compounds that expand these areas. Tripos’ high-throughput medicinal chemistry process will enable the rapid synthesis of those compounds to meet Sanofi-Synthelabo Recherche’s project time frame requirements.
“Tripos has long recognized the positive impact that high-quality starting points have on the drug discovery process,” said Dr. John P. McAlister, president and chief executive officer at Tripos. “Our aim is to enable Sanofi-Synthelabo Recherche to minimize time and attrition in the early phases of drug discovery by designing starting points that are structurally desirable and developable.”
“Sanofi-Synthelabo Recherche required a partner who could meet our exacting project criteria of quality, quantity, structural desirability and speed of delivery,” said Philippe Bovy, manager of chemical estate at Sanofi-Synthelabo Recherche. “Tripos’ integrated approach to compound design and synthesis, in conjunction with its proven experience in this area, made it the partner of choice.”
About Tripos, Inc.
Tripos (Nasdaq:TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Tripos collaborates with clients to accelerate and improve the creation of life-enhancing products. Within Tripos’ Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos’ Discovery Research (DR) business, Tripos’ medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at http://www.tripos.com .
